NEW YORK (GenomeWeb) – Cancer Genetics today announced a 24 percent jump in its third quarter revenues on strong performance in its biopharma services business.

For the three-month period ended Sept. 30, the Rutherford, New Jersey-based cancer diagnostics firm reported revenues of $4 million compared with $3.2 million in the same period last year, matching analysts' consensus estimate. Biopharma services revenues increased 35 percent to $2.6 million from $1.9 million, offsetting a $100,000 decline in clinical services revenue to $1.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.